济南阳痿能否治得好济南包茎长是什么样子,济南早泄治疗大概多少,济南前列腺发炎怎么办,济南阴囊与大腿内侧长疙瘩,济南切割包皮大概费用,济南尿道口有透明液体流出,济南看男科医院有

MOSCOW, Sept. 21 (Xinhua) -- A Russian Proton-M carrier rocket carrying a military spacecraft blasted off early Wednesday from the Baikonur space center in Kazakhstan, the first launch since a series setbacks of Russian rocket launch in August.Colonel Alexei Zolotukhin, spokesman of the Russian Space Forces, told reporters that the successful launch took place at 02:47 Moscow time (2247 GMT Tuesday) as scheduled."The spacecraft is scheduled to separate from the Briz-M booster at 11:48 Moscow time (0748 GMT)," Zolotukhin said.The military spacecraft delivered by the Proton-M belongs to the Russian Defense Ministry.Local reports said the Wednesday launch was originally planned for Aug. 31, but was postponed due to an investigation into a failed launch of a Proton-M rocket carrying an Express-AM4 satellite on Aug. 18.After the failure, Russia decided to suspend launches of rocket Proton-M pending the outcome of a probe into the accident.On Aug. 24, a Progress M-12M cargo ship also failed to reach the orbit due to a rocket malfunction. Russia delayed the launch of next manned spaceship to the International Space Station (ISS).

SINGAPORE, July 3 (Xinhua) -- The over 60 nursing homes in Singapore, especially those run by voluntary welfare organizations, are facing a bed crunch, local daily Straits Times reported on Sunday.The newspaper found in a check with 20 homes that more than half of the nursing homes were running at full or almost full capacity. Homes run by voluntary welfare organizations, where there are subsidized beds, have long waiting lists.The average waiting time for a bed in nursing homes run by voluntary welfare organizations rose from 50 days in 2008 to about 60 days early last year, the newspaper said.It is easier to get a bed in a privately run home, though only slightly and if you can afford it. Econ Healthcare Group, which runs eight nursing homes in Singapore, said the occupancy rate is 99 percent and it has waiting lists of up to 20 people at some branches.Demand for nursing homes in the city state can only grow given the aging population. By 2030, the number of people aged 65 or above is projected to reach 900,000, or one in every five residents.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 4 (Xinhua) -- Officials and delegations from China and African countries have gathered at a seminar being held in Beijing to discuss rural development and economic growth.The seven-day seminar kicked off on Sunday, attracting representatives from China and 11 African countries to exchange views and experiences related to the seminar's theme of "agriculture and rural development."Justin Lin Yifu, chief economist and senior vice president of the World Bank, said at the seminar's opening ceremony that African countries should take cues from China's experience in creating a series of policies to bolster agricultural and rural development, as these policies have also facilitated the country's economic growth.Hu Jinglin, assistant to China's Minister of Finance, said improved agricultural cooperation between China and Africa will help enhance global grain security.China has worked on 142 cooperative agricultural projects with 14 African countries to date. In addition, it has sent 104 agricultural experts to 33 African countries to train more than 4,200 local agricultural technicians.

BEIJING, Aug. 5 (Xinhuanet) -- A study conducted by Israeli researchers at the Albert Einstein College of Medicine in New York shows that genes, rather than good eating and lifestyle habits, determine longevity, according to media reports Friday. "This study suggests that centenarians may possess additional longevity genes that help to buffer them against the harmful effects of an unhealthy lifestyle," said senior author Nir Barzilai, director of the Institute for Aging Research at Yeshiva University's Albert Einstein College of Medicine.The study involves 477 Ashkenazi Jews between the ages of 95 and 122, of whom 75 percent are women. According to the study, Ashkenazi Jews are chosen as subjects because they are more "genetically uniform than other populations, making it easier to spot gene differences that are present."The study also found that the long-lived Ashkenazi Jews drank slightly more and exercised less than their average counterparts. But Barzilai also warned: “Although this study demonstrates that centenarians can be obese, smoke and avoid exercise, those lifestyle habits are not good choices for most of us who do not have a family history of longevity.""We should watch our weight, avoid smoking and be sure to exercise, since these activities have been shown to have great health benefits for the general population, including a longer lifespan," He added.